A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

NCT04246086 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

237

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Mosunetuzumab (IV)
DRUG: Tocilizumab
DRUG: Lenalidomide
DRUG: Mosunetuzumab (SC)

Sponsor

Hoffmann-La Roche